Eulo Vanessa, Van Tine Brian A
Division of Medical Oncology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Division of Medical Oncology, Washington University in St. Louis, St. Louis, MO 63110, USA.
Cancer Drug Resist. 2022 Apr 6;5(2):328-338. doi: 10.20517/cdr.2021.127. eCollection 2022.
The emergence of immunotherapy as a cancer therapy has dramatically changed the treatment paradigm of systemic cancer therapy. There have been several trials evaluating immune checkpoint blockade (ICI) in soft tissue sarcoma. While there is generally a limited response in sarcoma, a subset of patients has durable responses to immunotherapy. This is attributable to a variety of factors including histologic subtype, tumor-infiltrating lymphocytes, and the tumor microenvironment among others. There is ongoing translational and clinical research evaluating ICI resistance in sarcoma and identifying therapeutic strategies to overcome this resistance. Herein, we provide a review of the current data, proposed mechanisms of resistance, and potential approaches to overcome this resistance.
免疫疗法作为一种癌症治疗方法的出现，极大地改变了全身性癌症治疗的模式。已经有多项试验评估免疫检查点阻断（ICI）在软组织肉瘤中的应用。虽然肉瘤患者的反应通常有限，但有一部分患者对免疫疗法有持久反应。这归因于多种因素，包括组织学亚型、肿瘤浸润淋巴细胞和肿瘤微环境等。目前正在进行转化研究和临床研究，以评估肉瘤中的ICI耐药性，并确定克服这种耐药性的治疗策略。在此，我们对当前数据、提出的耐药机制以及克服这种耐药性的潜在方法进行综述。
